Sarepta Therapeutics tops estimates

Second quarter revenue for Sarepta Therapeutics Inc. (Nasdaq: SRPT) exceeded expectations by a wide margin prompting the biopharmaceutical to lift its full year forecast. The stock price leaped $6.85 to close at $40.93.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.